Remote ischaemic Conditioning After Stroke Trial (ReCAST)

Remote ischaemic Conditioning After Stroke Trial (ReCAST): a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86672015

Enrollment

Registered

2012-11-29

Start date

2013-03-04

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Stroke Research Network

Interventions

30 patients will be randomised on a 1:1 basis to receive either: Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (u

or Control group: 4 cycles of inflation and deflation up to 30mmHg in the non-paretic arm Follow up on Day 4 and Day 90.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. Clinical stroke (lacunar or cortical) of ischaemic subtype 3. Within 12 hours of stroke onset 4. Arm and/or leg weakness at the time of randomisation

Exclusion criteria

Exclusion criteria: 1. Premorbid dependency, modified Rankin scale (mRS) >3 2. Known subclavian or brachial artery stenosis 3. Dementia 4. Coma [Glasgow Coma Scale (GCS< 8)] 5. Malignancy or significant comorbidity 6. Participation in other drug trials 7. Pregnancy

Design outcomes

Primary

Measure	Time frame
Tolerability (duration cuff tolerated, number of cycles, drop out rate) and feasibility (accrual rate, proportion of patients knowing if they received RIC or sham) of RIC after hyperacute ischaemic stroke	—

Secondary

Measure	Time frame
Clinical safety (day 4±1, day 90±7): Serious adverse events (SAE); death (cause); recurrence/progression; neurological deterioration (increase in NIHSS >4 points); vascular events (including limb ischaemia, venous thrombo-embolism); neurovascular limb damage and tissue injury. Laboratory measures: (Day 0, day 4±1, day 90±7) Surrogate markers of efficacy, plasma S100B and MMP-9 levels by multiplex analysis; markers of inflammation and vascular function including but not limited to plasma CRP, e-selectin and vCAM by multiplex analysis; circulating endocannabinoids levels; plasma SOD activity by bioassay. Haemodynamic parameters: Transcranial Doppler (TCD), continuous recording during RIC, measures middle cerebral artery blood flow velocity/pulsatility index (a surrogate for cerebral blood flow (CBF)). Day 0 pre and post RIC, day 4±1 and day 90±7: central BP, pulse pressure, heart rate, rate-pressure product; aortic compliance and pulse wave velocity. Clinical efficacy: (Day 4±1, day 90±7) Impairment (NIHSS, motoricity index); dependency (modified Rankin Scale (mRS)); disability (Barthel Index(BI)<60)); functional independence (extended activities of daily living (EADL)); Zung depression scale; cognition (MMSE). At discharge/death: Length of stay in hospital; discharge disposition.	—

Measure

Time frame

Clinical safety (day 4±1, day 90±7): Serious adverse events (SAE); death (cause); recurrence/progression; neurological deterioration (increase in NIHSS >4 points); vascular events (including limb ischaemia, venous thrombo-embolism); neurovascular limb damage and tissue injury. Laboratory measures: (Day 0, day 4±1, day 90±7) Surrogate markers of efficacy, plasma S100B and MMP-9 levels by multiplex analysis; markers of inflammation and vascular function including but not limited to plasma CRP, e-selectin and vCAM by multiplex analysis; circulating endocannabinoids levels; plasma SOD activity by bioassay. Haemodynamic parameters: Transcranial Doppler (TCD), continuous recording during RIC, measures middle cerebral artery blood flow velocity/pulsatility index (a surrogate for cerebral blood flow (CBF)). Day 0 pre and post RIC, day 4±1 and day 90±7: central BP, pulse pressure, heart rate, rate-pressure product; aortic compliance and pulse wave velocity. Clinical efficacy: (Day 4±1, day 90±7) Impairment (NIHSS, motoricity index); dependency (modified Rankin Scale (mRS)); disability (Barthel Index(BI)<60)); functional independence (extended activities of daily living (EADL)); Zung depression scale; cognition (MMSE). At discharge/death: Length of stay in hospital; discharge disposition.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026